has decided to embark on the path of fine-tuning and developing rhNGF in its formulation for clinical use, at its own biotech facility in L’Aquila. and in Naples, where there are the laboratories of Drug Discovery and Technology Formulation, within a long-term collaboration with CNR. Italian excellence: the Dompé Hub in L’Aquila. Dompé has concentrated its manufacturing and research and development activities at its L’Aquila hub.
|Published (Last):||13 August 2004|
|PDF File Size:||1.29 Mb|
|ePub File Size:||10.56 Mb|
|Price:||Free* [*Free Regsitration Required]|
To achieve the ambitious goal of providing answers to health questions, the continual pursuit of excellence and the ability to work as a system are, in fact, critical.
Milano, 6 February The application of Smart Factory concepts in the pharma context, in fact, is accompanied by certain peculiarities linked to qualitative and regulatory aspects. Cenegermin is a human beta-nerve growth factor beta-ngf – – peptide non-covalent dimer produced in escherichia coli.
Our research | Dompé
The protein—in this case Nerve Growth Factor, NGF —is produced using a forkulation organism the bacterium Escherichia Coli of which the entire genome and the complex of biological interactions is known in detail. His dompr call him Open superstar worlddrugtracker. We suggest you to update it for free by following one of the these links, choosing the browser you prefer: This phase is followed by packaging in boxes, wrapping and pallets.
tormulation Thanks to the skills encompassed by this organisation, the CDMO can offer applied answers to genetic cloning, including the expression of coded proteins, their purification and characterisation and the issuance of the GMP of the Drug Substance.
It received European Union Formulwtion in July, for the treatment of moderate to severe neurotrophic keratitis. Inthe plant established new areas for a total usable surface of 8, square metres, including a four-storey building dedicated to the production process of coated granulates, a three-storey building for secondary packaging and a new warehouse.
The entire upstream process is carried out in controlled environments that guarantee sterility and bacterial containment. NGF was the first neurotrophic factor to be identified and purified and over the last fifty years, its role in neuronal development and its biological activity on neural tissue has been of great interest to science. In the first study, patients were randomized into three different groups. In particular the study dealt with the mathematical modelling of the biotech fermentation process for the production of NGF having used AI techniques.
There are seven packaging lines in total for synthetic pharmaceutical products: It is proposed that these integrated platforms will concentrate, above all, on developing new drugs for pathologies that still do not have effective treatments. The biotechnological active ingredient rhNGF is produced here and marketed in Italy and Europe for the treatment of neurotrophic keratitis. The proNGF has an additional protein chain pro that has the difficult task of assisting the correct folding of the protein.
The prevalence of neurotrophic keratitis has been estimated to be less than five in 10, individuals. In humans, NGF is naturally produced as pre-pro-peptide, secreted into the foemulation reticulum and cleaved by furin protease.
The safety and efficacy of Oxervate, a topical eye drop containing cenegermin, was studied in a total of patients with neurotrophic keratitis in two, eight-week, randomized controlled multi-center, double-masked studies.
We suggest you to update it for free by following one of the these links, choosing the browser you prefer: Subsequently they are homogenised in order to favour cellular rupture and the recovery of the inclusion bodies which contain the protein.
Our story | Dompé
The intervention concerned gormulation creation of new areasconsisting of a four-storey building dedicated to the production process of coated granules, a three-storey building for packaging and a formilation warehouse. Biotechnological production comprises one upstream phase the production of the active principle from biological material and one downstream phase purification.
In this phase the fermentation volume grows from a few litres initially up to litres, and in the end the proNGF gene is activated and begins the real protein production.
The facility thus has the capacity to develop, transfer and validate most of the analytical methods needed for issuing GMPs and characterising biomolecules. Domps this point we move on to the second phase of packaging in boxes, wrapping and pallets.
The areas of activity are: Several laboratories are up and running at CDMO, for analytical development and quality control, making it possible to conduct the most in-depth analyses in the biotechnology field. In the first study, only patients with the disease in one eye were enrolled, while in the second study, patients with the disease in both eyes were treated in both eyes bilaterally.
In the turnover was million is focused both on the development of pharmaceuticals for therapeutic needs as yet unfulfilled, in the areas of ophthalmology, oncology, diabetes and organ transplant, as well as in the creation of innovative industrialisation processes of these. You are going to leave this site. The fermentation phase lasts approximately three days, during which the bacterial cells multiply exponentially, also duplicating the gene for the production of proNGF.
The site covers an area ofsquare metres. Join 2, other followers.